Adenoviral-mediated pHyde genetransfer and cisplatin additively inhibit human prostate cancer growth by enhancing apoptosis

Prostate

Volumn 69, Issue 3, 2009, Pages 234-248

  Lu, Yi ^a,d   Zhang, Xiongwen ^a,b   Beheshti, Ben ^c   Zhang, Jun ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Adenovirus; Apoptosis; Cisplatin; Phyde; Prostate cancer

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; COMPLEMENTARY DNA; DNA; DOCETAXEL; MEMBRANE PROTEIN; ANTINEOPLASTIC AGENT; CASPASE 3; MESSENGER RNA; ONCOPROTEIN; TAXOID; TSAP6 PROTEIN, HUMAN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTITUMOR GENE; APOPTOSIS; ARTICLE; AUDIOVISUAL EQUIPMENT; BACTERIAL GENE; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CELL DEGENERATION; CELL GROWTH; CELL LINE; CELL MATURATION; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CELL MOTION; CHROMOSOME 2Q; CONTROLLED STUDY; DATA BASE; DNA LIBRARY; DNA SEQUENCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE LOCATION; GENE LOCUS; GENE MAPPING; GENE TRANSFER; GENOMICS; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN CHROMOSOME; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYDE GENE; PRIORITY JOURNAL; PROSTATE CANCER; SCREENING; SEQUENCE ANALYSIS; STEM CELL; TISSUE DIFFERENTIATION; ADENOVIRUS; ANIMAL; CELL DIVISION; CHEMISTRY; DRUG EFFECT; GENE THERAPY; GENETICS; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; PROTEIN TERTIARY STRUCTURE; RAT; SEQUENCE HOMOLOGY; TUMOR CELL LINE;

ADENOVIRIDAE; AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; CASPASE 3; CELL DIVISION; CELL LINE, TUMOR; CELL MEMBRANE; CISPLATIN; COMBINED MODALITY THERAPY; DNA, COMPLEMENTARY; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; MALE; ONCOGENE PROTEINS; PROSTATIC NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RATS; RNA, MESSENGER; SEQUENCE HOMOLOGY; TAXOIDS;

EID: 60849083246     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20867     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2007;57:43-66.
2. Carter BH, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 1990;143:742-746.
3. Sandberg AA. Chromosome abnormalities and related events in prostate cancer. Hum Pathol 1992;23:368-380.
4. Steiner MS, Zhang X, Wang Y, Lu Y. Growth inhibition of prostate cancer by adenovirus expressing a novel tumor suppressor gene pHyde. Cancer Res 2000;60:4419-4425.
5. Lu Y, Lotan R. Transcriptional regulation by butyrate of mouse galectin-1 gene in embryonal carcinoma cells. Biochim Biophys Acta 1999;1444:85-91.
6. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990;215:403-410.
7. Akeson EC, Davisson MT. Chromosome preparation from solid adult tissues or tumors. In: Dracopoli NC, Haines JL, Korf BR, Moir DT, Morton CC, Seidman CE, Seidman JG, Smith DR, editors. Current protocols in human genetics. New York: John Wiley & Sons, Inc; 2000. pp. 4.10.8-4.10.9.
8. Lu Y, Carraher J, Zhang Y, Armstrong J, Lerner J, Roger W, Steiner MS. Delivery of adenoviral vectors to the prostate for gene therapy. Cancer Gene Ther 1999;6:64-72.
9. Graham FL, Prevec L. Manipulation of adenovirus vectors. In:Murray EJ, editor. Methods in molecular biology, gene transfer and expression protocols. New Jersey: The Human Press Inc;1991. pp. 109-128.
10. Lu Y, Lotan D, Lotan R. Differential regulation of constitutive and retinoic acid-induced galectin-1 gene transcription in murine embryonal carcinoma and myoblastic cells. Biochim Biophys Acta 2000;1491:13-19.
11. 2+channels. Annu Rev Cell Dev Biol 2000;16:521-555.
12. Schwartz A. Molecular studies of the calcium antagonist binding site on calcium channels. Am J Cardiol 1994;73:12B-14B.
13. Catterall W, Epstein PN. Ion channels. Diabetologia 1992;35:23-33.
14. Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC,Madraswala R, Zhou Y, Kuo J, Raitano AB, Jakobovits A, Saffran DC, Afar DE. STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci USA 1999;96:14523-14528.
15. Wissenbach U, Niemeyer BA, Fixemer T, Schneidewind A, Trost C, Cavalie A, Reus K, Meese E, Bonkhoff H, Flockerzi V. Expression of CaT-like, a novel calcium-selective channel,correlates with the malignancy of prostate cancer. J Biol Chem 2001;276:19461-19468.
16. Rosenberg B. Fundamental studies with cisplatin. Cancer 1985;55:2303-2306.
17. Lee CK, Park KK, Lim SS, Park JH, Chung WY. Effects of the licorice extract against tumor growth and cisplatin-induced toxicity in a mouse xenograft model of colon cancer. Biol Pharm Bull 2007;30:2191-2195.
18. Culine S, El Demery M, Lamy PJ, Iborra F, Avances C, Pinguet F. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 2007;178:844-848.
19. Sakura M, Tsukamoto T, Yonese J, Ishikawa Y, Aoki N, Fukui I. Successful therapy of a malignant phyllodes tumor of the prostate after postoperative local failure. Urology 2006;67:845.e11-845.e13.
20. Weber B, Serafin A, Michie J, Van Rensburg C, Swarts JC, Bohm L. Cytotoxicity and cell death pathways invoked by two new rhodium-ferrocene complexes in benign and malignant prostatic cell lines. Anticancer Res 2004;24:763-770.
21. Urakami S, Shiina H, Sumura M, Honda S, Wake K, Hiraoka T,Inoue S, Ishikawa N, Igawa M. Long-term control or possible cure? Treatment of stage D2 prostate cancer under chemotherapy using cisplatin and estramustine phosphate followed by maximal androgen blockade. Int Urol Nephrol 2008; 40:365-368.
22. Moriyama-Gonda N, Shiina H, Terashima M, Satoh K, Igawa M. Rationale and clinical implication of combined chemotherapy with cisplatin and oestrogen in prostate cancer: Primary evidence based on methylation analysis of oestrogen receptor-alpha. BJU Int 2008;101:485-491.
23. Sessa C, Minoia C, Ronchi A, Zucchetti M, Bauer J, Borner M, de Jong J, Pagani O, Renard J, Weil C, D'Incalci M. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. Ann Oncol 1998;9:1315-1322.
24. Culine S, El Demery M, Lamy PJ, Iborra F, Avancès C, Pinguet F. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 2007;178:844-848.
25. Hayes-Lattin BM, Kovach PA, Henner WD, Beer TM. Successful treatment of metastatic hormone-refractory prostate cancer with malignant pericardial tamponade using docetaxel. Urology 2002;59:137-138.
26. Zhang Z, Stanfield J, Frenkel E, Kabbani W, Hsieh J-T. Enhanced therapeutic effect on androgen-independent prostate cancer by depsipeptide (FK228), a histone deacetylase inhibitor, in combination with docetaxel.
27. ang C, Cirielli C, Capogrossi MC, Passaniti A. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 1995;55:4210-4213.
28. Hedlund TE, Meech SJ, Srikanth S, Kraft AS, Miller GJ, Schaack JB, Duke RC. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. Cell Death Differ 1999;6:175-182.
29. Hyer ML, Voelkel-Johnson C, Rubinchik S, Dong J-Y, Norris JS. Intracellular Fas ligand expression causes Fas-mediated apop-tosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Mol Ther 2000;2:348-358.
30. Dorai T, Perlman H, Walsh K, Shabsigh A, Goluboff ET, Olsson CA, Buttyan R. A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells. Int J Cancer 1999;82:846-852.
31. Gurnani M, Lipari P, Dell J, Shi B, Nielsen LL. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother Pharmacol 1999;44:143-151.
32. Hamada M, Fujiwara T, Hizuta A, Gochi A, Naomoto Y, Takakura N, Takahashi K, Roth JA, Tanaka N, Orita K. The p53 gene is a potent determinant of chemosensitivity and radio-sensitivity in gastric and colorectal cancers. J Cancer Res Clin Oncol 1996;122:360-365.
33. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994;54:2287-2291.
34. Adams C, Lu Y, Steiner MS, Allay JA. Adenovirus-mediated p16 expression and cisplatin synergize to inhibit human prostate cancer xenograft growth. Mol Ther 2000;1:163.
35. Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds; A new class of potent antitumor agents. Nature 1969;222:385-386.
36. Chao D, von Schlippe M, Harland SJ. A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: An active new regimen. Eur J Cancer 1997;33:1230-1233.
37. Geldof AA, Slotman BJ. Radiosensitizing effect of cisplatin in prostate cancer cell lines. Cancer Lett 1996;101:233-239.
38. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993;8:307-318.
39. Wang X, Liu Y, Chow LS, Wong SC, Tsao SW, Kwong DL, Wang J, Sham JS, Nicholls JM. Cisplatin-induced p53-independent growth arrest and cell death in cancer cells. Int J Oncol 1999;15:1097-1102.
40. Porkka KP, Nupponen NN, Tammela TLJ, Vesselia RL, Vishkorpi T. Human pHyde is not a classical tumor suppressor gene in prostate cancer. Int J Cancer 2003;106:729-735.
41. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998;95:5246-5250.
42. Orrenius S, Nicotera P. The calcium ion and cell death. J Neural Transm Suppl 1994;43:1-11.
43. Tapia-Vieyra JV, Mas-Oliva J. Apoptosis and cell death channels in prostate cancer. Arch Med Res 2001;32:175-185.
44. Wissenbach U, Bodding M, Freichel M, Flockerzi V. Trp12, a novel Trp related protein from kidney. FEBS Lett 2000;485:127-134.
45. Elble RC, Pauli BU. Tumor suppression by a pro-apoptotic calcium-activated chloride channel in mammary epithelium. J Biol Chem 2001;276:40510-40517.
46. Tseng CP, Ely BD, Li Y, Pong RC, Hsieh JT. Regulation of rat DOC-2 gene during castration-induced rat ventral prostate degeneration and its growth inhibitory function in human prostatic carcinoma cells. Endocrinology 1998;139:3542-3553.
47. Luo J, Lubaroff DM, Hendrix MJ. Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection. Cancer Res 1999;59:3552-3556.
48. Kleinerman DI, Zhang WW, Lin SH, Nguyen TV, von Eschenbach AC, Hsieh JT. Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: A preclinical study. Cancer Res 1995;55:2831-2836.